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Abstract
Global Cancer Mortality: National Healthcare System Resources and Survival from Cancer
Ali Batouli1, Pooya Jahanshahi, Cary Gross, Danil V Makarov, James B. Yu. Department
of Radiation Oncology. Yale University, School of Medicine, New Have, CT
Cancer continues to rise steadily as a contributor to premature death in the
developing world. Despite this, little is known about what aspects of national
healthcare systems are associated with reduced mortality from cancer. Thus, we aimed
to investigate the relationship between national healthcare system resources and
cancer mortality.

The most recent estimates of cancer incidence and deaths were

obtained for the 85 countries with reliable data. We defined cancer mortality to
incidence ratio as deaths per year divided by incidence per year for a given cancer.
Countries were categorized according to high (GDP>$15,000) or low-income
(GDP<$15,000), and a multivariate linear regression model was used to determine the
association between healthcare system indicators and cancer-specific mortality to
survival ratio. Indicators studied included per capita gross domestic product (GDP),
overall healthcare expenditure, health expenditure as a proportion of GDP, total
external beam radiotherapy devices per capita (TEBD), physician density, and the year
2000 World Health Organization (WHO) healthcare system rankings.
The overall cancer mortality to survival ratio in high income countries (47%)
was significantly lower than that of low income countries (64%), with a p<0.0001. In
high income countries, GDP, health expenditure and TEBD showed significant inverse
correlations with overall cancer mortality to survival ratio, with health expenditure
(overall and as a proportion of GDP)

showing the strongest relationship. For overall

cancer, a $3,040 increase in GDP (p=0.004), a $379 increase in THE (p<0.0001), a 0.75%
increase in THE per GDP (p<0.001) or an increase of 0.59 TEBD 100,000 population
(p=0.027) were all associated with a 1% decrease in mortality to survival ratio.

In

low income countries, only WHO score correlated with decreased overall cancer
mortality to survival ratio (p=0.022).
Our analysis suggests that WHO healthcare score is associated with improved
cancer outcomes in low income countries while absolute levels of financial resources
and infrastructure play a more important role in high income countries.
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Introduction
Cancer is an important global problem, especially in the
developing world. Greater than half of cancer cases worldwide arise in
developing countries, and this proportion is expected to rise to 70% by
2020 (1). As cancer incidence and mortality rates increase in the
developing world on a yearly basis (2), the United Nations and WHO have
placed greater emphasis on its treatment and prevention. September 2011
marked the first ever High-Level Meeting of the United Nations on noncommunicable diseases, where researchers and policy makers united to
forge new policies to tackle the growing worldwide epidemic of chronic
disease.

This meeting will took place without essential data on the

specific aspects of national healthcare systems that are associated
with the variation of cancer mortality worldwide.
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Given the cultural, socioeconomic, and environmental factors that
can influence cancer outcomes, it is unclear whether and to what extent
healthcare expenditure, infrastructure and organization are associated
with cancer mortality rates.

Assessing overall health expenditure is

perhaps the simplest method to measure a country’s commitment to
healthcare.

Studies have shown weak but significant relationships

between healthcare spending and improved cancer mortality in particular
subsets of developed countries (3) (4), but this association is
unexplored in the developing world.
In addition to being associated with overall expenditure, cancer
mortality may be affected by the specific aspects of healthcare
infrastructure towards which spending is geared. Healthcare
infrastructure can be measured in several ways.

In the developed

world, the number of doctors per capita has been found to be associated
with cancer mortality in some studies (3) but not in others (4). In
addition to physician density, a useful measure of healthcare
infrastructure is access to radiation therapy (5).

Radiation therapy

is often underutilized in developing countries due to the up-front
expense of required machines and facilities. In fact, 22 countries in
Africa and Asia have no radiation therapy facilities at all, with many
6

more having only a fraction of the machines required by their
populations (6). However, it is unclear whether access to radiation
oncology facilities actually correlates with reduced cancer mortality
worldwide.
The overall functionality of a national healthcare system is
another factor that could potentially affect cancer mortality. The year
2000 World Health Organization (WHO) overall healthcare system rankings
for example provided a systematically derived, quantifiable measure of
healthcare system fairness and effectiveness. The rankings aimed to use
available data from around the world to assess the effectiveness of 191
countries in “Improving health, reducing health disparities,
protecting households from impoverishment due to medical expenses, and
providing responsive services that respect the dignity of patients,”
(7). The ranking was a complex indicator that was based on the
following factors: healthcare system responsiveness (based on overall
patient satisfaction and the ability of a system to act promptly and
effectively), the distribution of responsiveness (e.g. in rich vs.
poor), overall level of health (measured by average disability adjusted
life years), the distribution of health, and finally, the fairness of
distribution of the financial burden of a system. Interestingly, they
7

ranked the USA, the nation spending the highest amount of money per
capita on healthcare at the time, 37th (8). As a result of this
surprising finding as well as debate within the scientific and
political community regarding the methodology and utility of the
rankings, little research has been done to see the effectiveness of the
rankings in predicting national health outcomes. Indeed, no study to
date has measured the association between these rankings and cancer
mortality.

Statement of Purpose
The goal of this study was two-fold: to see the extent to which
cancer mortality varied throughout the world and to identify the
relation between healthcare system factors and cancer outcomes in both
developed and developing countries. Broadly, we assessed three
categories of variables with cancer mortality: overall monetary
resources, healthcare system infrastructure, and the WHO’s overall
healthcare system score. Due to the vast disparities in resources,
healthcare systems and disease burdens in the developed vs. developing
world, we hypothesized that factors affecting outcomes in low income
countries would differ from those in high income countries. Thus we
8

assessed the healthcare system correlates of cancer mortality in each
group separately.
Methods
Outcome Variable
Age standardized cancer incidence and death rates were obtained
from the International Agency for Research on Cancer’s Globocan 2008
database, which included the most recent data from each country
worldwide. While incidence data was available for a majority of
countries, only 85 countries had recent (post 2005) non-estimated
mortality data and were thus included for analysis. Of these 85
countries, 41 were in Europe, 24 in the Americas, 17 in Asia, 2 in
Oceania and only 1 in Africa. Data were stratified by cancer type, sex,
and age, with groupings from 0-14 years, 15-39 years, 10 year groups
until age 70, and 70+ years. As there are no standard international
definitions of race and ethnicity, data were not stratified by race.
There were 28 different cancer types reported, 26 in women and 24 in
men. However, data from Kaposi Sarcoma was excluded from the evaluation
as only two countries included this data, leading to a total of 27
cancer types analyzed, 25 in women and 24 in men. Additionally, each
country had a summary measure for all cancers excluding non-melanoma
9

skin cancer (overall cancer). The mortality to incidence ratio (M/I)
was determined by dividing a given year’s mortality for a cancer by
the cancer’s incidence in that year. While this is not an exact
measure of survival, since being diagnosed with cancer in one year can
lead to mortality in a different year, and incidence can change
significantly from year to year, it is a simple and straightforward
approximation that is useful for large datasets.
While a very broad range of countries from all continents are
included, the poorest of poor countries, including all countries with
GDPs of less than $1,690, were not included due to their lack proper
and accurate cancer incidence and mortality databases. This list of
excluded countries consists of all but one country in Africa, as well
as many countries across Asia and Latin America.

Table 1. Variables Used in Regression model
Independent Variable
WHO healthcare
system score (overall
and responsiveness)

Source

Description
The score was based on a system’s responsiveness to
patients, the fairness of financial distribution, the overall
national level of health, and the distribution of health

THE per GDP

WHO World Health Report 2000
WHO Global Atlas of the Health
Workforce 2008
World Development Indicators
database, World Bank (2007)
World Development Indicators
database, World Bank (2007)
World Development Indicators
database, World Bank (2007)

Radiation Therapy

International Atomic Energy Agency’s

Physician Density
Gross Domestic
Product (GDP)
Total Health
Expenditure (THE)

Estimated number of physicians per 100,000 population
Estimated purchasing parity gross domestic product per
capita in US$
Estimated total (government and private) health
expenditure per capita in US$
Estimated percent of THE as a proportion of GDP
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total external beam radiotherapy devices per capita

Directory for Radiotherapy 2010

(TEBD)

Control Variable

Source

Description

HIV rate

CIA World Factbook 2003-2008
UN World Urbanization Prospects
(2007)

Estimated percent of population infected by HIV

Estimated per capita liters of ethanol consumed

Female smoking rate

WHO Core Health Indicators 2003
WHO Report on the Global Tobacco
Epidemic 2007
WHO Report on the Global Tobacco
Epidemic 2008

Male obesity rate

WHO Global Database on BMI (2008)

Estimated percent of men who have a BMI>30

Female obesity rate

WHO Global Database on BMI (2008)

Estimated percent of women who have a BMI > 30

Rural population
Ethanol consumption
Male smoking rate

Estimated percent of population that live in rural area

Estimated percent of men who smoke tobacco regularly
Estimated percent of women who smoke tobacco
regularly

Table 1 shows the independent variables and control variables that were used in the
regression model, as well as the source and description of each variable.

Table 2. Summary statistics by region for high and low income countries
Category

Organization
Financial
Resources

Healthcare
Infrastructure

Variable

Region

High Income
Countries

Eastern
Europe

Western
Europe

North
America

Eastern
Asia

Western
Asia

Oceania

Overall

Countries

12

18

5

5

2

2

44

Mortality

55%

40%

50%

49%

49%

39%

47%

WHO Rank

61

16

55

29

37

37

36

GDP

$21,043

$38,612

$31,212

$38,197

$42,393

$32,569

$32,418

THE

$1,174

$4,451

$2,989

$1,552

$1,397

$3,388

$2,824

THE per GDP

5.30%

11.40%

8.20%

4.60%

4.10%

10.40%

8.10%

TEBD

3.4

6

5.9

2

2.5

5.8

4.7

Physician
Density

322

347

150

159

274

230

284
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Organization

Financial
Resources

Healthcare
Infrastructure

Low Income
Countries

Eastern
Europe

North
America

Central
America

South
America

Eastern
Asia

Western
Asia

Africa

Overall

Countries

11

1

6

12

4

6

1

41

Mortality

65%

61%

62%

59%

68%

73%

70%

64%

WHO Rank

76

61

77

72

99

121

175

92

GDP

$8,951

$12,447

$7,340

$9,397

$4,893

$5,616

$10,63
2

$7,543

THE

$387

$564

$257

$406

$93

$126

$497

$269

THE per GDP

4.10%

4.50%

3.40%

4.10%

2.00%

2.10%

4.70%

3.40%

TEBD

1.6

1

0.8

1.7

0.8

1.1

1.2

1.2

Physician
Density

210

198

106

202

139

241

77

215

Table 2 shows the mean for each variable used in the regression model (excluding
controls) by region and income category. High income countries had a GDP > $15,000
while low income countries’ were below $15,000. All variables varied widely by region
and income category. Overall, low income countries also had lower levels of resources
and higher mortality than high income countries. Within high income countries, E.
Europe had the worst mortality at 55% while Oceania and W. Europe had the best at 3940%. (p=0.006). Within low income countries, The Americas had lower mortalities than
E. Europe and Asia . W. Asia, composed of former soviet states, had the highest
mortality of any region at 73%. (Mortality = Overall cancer mortality, GDP = Gross
Domestic Product per capita, WHO = World Health Organization, THE = total health
expenditure per capita, TEBD = Total external beam radiation devices per 100,000
population, Physician Density = Physicians per 100,000 population)

Independent Variables:
As previously mentioned, the markers chosen to correlate with
cancer survival were World Health Organization (WHO) overall healthcare
system score and system responsiveness score, physician density, per
capita Gross Domestic Product (GDP), per capita total healthcare
expenditure (THE), access to radiation oncology (measured by total
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external beam devices (TEBD)

per capita) and THE per GDP. Table 1

lists all indepndent variables as well as all control variables used in
the study, with a listing of each variable's source. Table 2 shows the
mean and ranges for the above variables overall and by region for both
low and high income countries.
WHO rankings
The first variable of interest was the year 2000 WHO overall
healthcare system rankings (OHS), which ranked the USA, the nation
spending the highest amount of money per capita on healthcare at the
time, 37th (8). As previously mentioned, the ranking itself was derived
from a score based on several variables: the system’s responsiveness
to patients, the fairness of financial distribution, the overall
national level of health, and the distribution of health. The
responsiveness measure included two major components: respect for
persons and client orientation. Fairness of financial distribution
measured the relative out of pocket amount paid by the rich and poor.
The overall national level of health was counted as the average
disability adjusted life expectancy (DALE) of the nation. The
distribution of health was concerned with the
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variance of DALE around the mean. Our study took into account the
overall healthcare system ranking as well as the specific measure of
responsiveness to patients, as this measure was most likely to affect
prompt diagnosis and treatment of malignancies. For statistical
reasons, the absolute scores on which the ranks were based were used in
the analysis.
Physician Density
In addition to overall healthcare system scores, physician
density plays a potentially important role in health outcomes.
Theoretically, a greater number of physicians per capita would result
in an increase of access of a population to physicians, and thus
potentially earlier and more effective treatment of cancer. Previous
studies on the subject have been equivocal. Or 2001 found that an
increase in physicians per capita in 29 Organization for Economic
Cooperation and Development (OECD) countries was associated with a
significant reduction in potential years of life lost by cancer
mortality in women, but not in men (3). Quaglia et al. 2005 on the
other hand found that in 23 European countries, the density of
healthcare employees did not correlate with improved cancer survival
among the elderly (4). Thus the question still remains as to whether,
14

globally, there is an association between physician density and cancer
survival. Our study used the measure of physicians per 100,000
population as recorded in the WHO Global Atlas of the Health Workforce
(9).
GDP, THE & THE per GDP
Greater human resources are not the only part of a healthcare
system that could provide improved outcomes. More financial resources
on a national level theoretically allow for improved cancer prevention
and treatment. Or 2001 showed a significant inverse relationship
between GDP and years of life lost by cancer mortality in OECD
countries (3). Quaglia et al. 2005 showed a significant positive
correlation between both GDP and THE and cancer survival in European
elderly (4). However, both studies only included a small cohort of
countries and in the latter, a specific age population. This study
aimed to see whether these trends hold on a more global scale. Per
capita GDP and THE were based on 2007 World Bank estimates (10).
Additionally, this study aimed to measure whether the importance of
healthcare in a given society, as measured by the percent of GDP spent
on THE (THE per GDP), correlated with cancer survival separate from
either THE or GDP alone.
15

Radiation Therapy
With the question of cancer, not only are the number of
physicians and the amount of spending on treatment potentially
important to outcomes, but also where that spending goes. The three
most common treatment modalities for any carcinoma are chemotherapy,
surgery, and radiation therapy, with each type of carcinoma more
responsive to one particular or a specific combination of treatments.
Radiation therapy (RT) in particular has often been severely
underutilized in developing countries, in large part due to the upfront expense of required machines and facilities. As such, 22
countries in Africa and Asia have no RT facilities at all, with many
more having far fewer machines than required by their populations (6).
In Africa for example, the supply of megavoltage radiation therapy
machines was 18% of the estimated need (6). Despite large startup costs
however, external beam radiation therapy in the long term is one of the
most effective and cost effective cancer treatments (5). The speed and
ease of treatment as well as the lack of need for expensive
chemotherapeutic agents or dangerous surgeries make this a potentially
excellent option for cancer treatment in developing countries. However,
no study has been done to show whether access to radiation oncology
16

facilities actually correlates to improved health outcomes and improved
cancer survival. Our study aimed to correlate survival with total
external beam devices per capita (TEBD), both Linear Accelerators and
Cobalt machines. TEBD data was obtained from the International Atomic
Energy Agency’s Directory for Radiotherapy Centers, a detailed list of
radiation therapy resources by country.
Data Analysis
Multivariate regression modeling was performed using Stata
version IC10 with the response variable of age standardized M/I. Three
separate models were created for each cancer and predictor variable
combination: one for males, one for females and one for both sexes
combined. As this study aimed to assess predictors of overall cancer
care, the summary measure of overall cancer M/I was the variable of
greatest interest. However, analysis was done on all cancers
individually as well to see whether any results found for overall
cancers held for individual cancers. This step was performed to
mitigate the potential confound caused by some countries having a
higher incidence of more deadly cancers as a proportion of overall
cancer incidence than others, thus artificially increasing their M/I.
Each model included adjustments for the behavioral, demographic and
17

environmental risk factors listed in Table 1. Since GDP, THE and TEBD
were collinear variables (pearson correlation coefficient>0.7 or < 0.7), they were not included in each other’s models. However,
physician density was included in all models as a control, as it was
not collinear with the other predictor variables. See Table 3 for
correlations between all predictor and control variables.
It was hypothesized that the relationship between predictor
variables and M/I would be different in lower vs. higher income
countries, thus the 85 countries were split roughly in half at the GDP
point of $15,000 and the above regressions were repeated for the high
and low GDP categories. Further breakdown into smaller GDP categories
was not performed due to diminishing power. Correlation coefficients,
regression coefficients and p-values were recorded for each regression
equation. The amount of change needed in a given predictor variable to
cause a 1% decrease in M/I was calculated by dividing 0.01 by the
regression coefficient.
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Responsiveness
Score

0.68

Physician Density

0.26

0.19

GDP

0.68

0.75

0.24

THE

0.63

0.71

0.36

0.83

TEBD

0.63

0.70

0.42

0.70

0.87

THE per GDP

0.63

0.66

0.40

0.66

0.93

0.87

HIV Rate

-0.30

-0.06

-0.25

-0.08

-0.10

-0.12

-0.08

Rural population
Ethanol
Consumption

-0.50

-0.49

-0.24

-0.57

-0.45

-0.49

-0.44

0.04

0.34

0.44

0.36

0.35

0.47

0.52

0.53

-0.03

Male Smoking

-0.26

-0.22

-0.26

0.26

-0.14

-0.24

-0.21

-0.28

-0.14

0.16

0.01

Female Smoking

0.45

0.37

0.47

0.36

0.44

0.46

0.51

-0.15

-0.43

0.57

0.15

Male Obesity

0.42

0.30

0.09

0.32

0.30

0.34

0.32

-0.08

-0.39

0.22

-0.15

0.45

Female Smoking

0.02

-0.13

-0.22

-0.08

-0.07

-0.04

-0.04

0.18

-0.16

-0.03

-0.09

0.11

Table 3 Shows the correlation between all variables, independent and control, used in
the regression models. Correlations that are shown in bold (the vast majority) are
significant, while correlations that are underlined meet the criteria for colinearity
(r>=0.70) and were thus not included in each other's linear regression models. GDP,
THE, THE per GDP, TEBD and WHO responsiveness score all showed significant colinearity
with each other.
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Male Obesity

Female Smoking

Male Smoking

Ethanol Consumption

Rural population

HIV Rate

THE per GDP

TEBD

THE

GDP

Physician Density

Responsiveness Score

WHO Overall Score

Table 3. Correlation Coefficients Between All Variables

0.58

Results
Overall monetary resources, healthcare system infrastructure,
healthcare system organization and overall cancer mortality varied
significantly between high and low income countries, and from region to
region, even within income categories (Table 2). Overall, low income
countries also had lower levels of financial resources and
infrastructure, as well as lower WHO healthcare scores and higher
mortality than high income countries (p<0.0001 for all variables
studied). Within high income countries, E. Europe had the worst
mortality at 55% while Oceania and W. Europe had the best at 39-40%.
(p=0.006). Within low income countries, the Americas had lower
mortalities (59-62%) than E. Europe and Asia. W. Asia, composed of
former soviet states, had the highest mortality of any region at 73%.
Figure 1 shows a map representation of the overall cancer mortality to
incidence ratios. Many of the highest mortality rates are found in
former or current communist countries in Eastern Europe and Western
Asia. In low income countries, mortality ranged from a low of 56% in
Costa Rica to a high of 78% in Armenia with a median of 64% in
Guatemala. In high income countries mortality ranged from a low of 38%
20

in Australia to a high of 73% in Greece with a median of 50% in Sweden.
The United States and Luxembourg, the two largest healthcare spenders
globally, were tied for second at a 39% overall mortality rate. A list
of all countries studied ranked by overall cancer mortality to
incidence ratios is shown in Table 4.
Several variables correlated significantly with M/I in the
regression models. The results for overall cancer are outlined in Table
5 and each variable is addressed individually below. It is interesting
to note that for every variable that proved significant, the
correlation was stronger (lower p-value) in men than in women, showing
that all variables had greater predictive value in the former.
WHO Scores
For low income countries, only WHO overall score correlated
significantly with overall cancer M/I, and only in the combined
statistic for both sexes, but not in each sex individually. A 1%
decrease in overall cancer mortality to incidence ratio correlated with
a 7.0% increase in WHO overall healthcare system score (p=0.022). In
high income countries, WHO overall score correlated with improved
outcome in stomach, testicular and head and neck cancers only, but not
overall cancer. WHO responsiveness score on the other hand, correlated
21

poorly with M/I in low income countries. In high income countries,
responsiveness score did correlate significantly with overall cancer
rate in all three sex categories.
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Figure 1. World Map By Age-adjusted Mortality to Incidence Ratios

Figure 1 shows a color coded map of age-adjusted mortality to incidence ratios (M/I)
for all cancers. Lighter colors correspond with lower mortality rates. As seen
numerically in Table 2, Western Europe, Oceania and North America have the lowest M/I.
In low income countries, Central and South America have lower M/I than much of
Eastern Europe and Asia. Many of the highest M/I are found in former or currently
communist countries in Eastern Europe and Western Asia.
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Table 4. Ranking of Countries by Overall Cancer Mortality per Incidence
Rank

Country

M/I

Rank

1

Australia

38.26%

30

2

Luxembourg

38.61%

3

United States

39.37%

4

New Zealand

5

Country

Mortality

Rank

Country

M/I

Costa Rica

55.54%

59

Guatemala

64.41%

31

Suriname

32

Japan

55.58%

60

Hungary

64.61%

55.64%

61

El Salvador

64.95%

40.55%

33

Portugal

56.31%

62

Belize

65.07%

Ireland

40.61%

34

Brunei

56.69%

63

Moldova

65.25%

6

Israel

40.79%

35

Venezuela

57.51%

64

Trinidad and Tobego

65.27%

7

Republic of Korea

40.87%

36

Argentina

57.75%

65

Albania

65.69%

8

Iceland

42.48%

37

Bahamas

57.97%

66

Belarus

65.82%

9

Finland

42.78%

38

Colombia

58.14%

67

Ecuador

65.88%

10

Norway

42.97%

39

Bulgaria

58.41%

68

Poland

65.91%

11

Canada

43.64%

40

Slovenia

58.62%

69

Romania

66.12%

12

France

43.78%

41

Lithuania

59.23%

70

Russian Fed

66.38%

13

Kuwait

44.19%

42

Brazil

59.25%

71

Mauritius

66.57%

14

Germany

44.22%

43

Uruguay

59.31%

72

Cuba

67.34%

15

Switzerland

45.11%

44

Nicaragua

59.85%

73

South Africa

68.93%

16

Belgium

46.82%

45

Paraguay

60.09%

74

China

69.26%

17

Singapore

47.24%

46

Barbados

60.14%

75

Turkmenistan

69.93%

18

Cyprus

47.25%

47

FYR Macedonia

60.24%

76

Kyrgyzstan

70.21%

19

Italy

48.71%

48

Croatia

60.42%

77

Uzbekistan

70.40%

20

Denmark

48.89%

49

Dominican Republic

60.88%

78

Serbia

71.30%

21

Sweden

49.67%

50

Mexico

60.94%

79

Georgia

71.37%

22

The Netherlands

49.74%

51

Ukraine

61.14%

80

Mongolia

72.76%

23

Czech Republic

50.95%

52

Chile

61.39%

81

Tajikistan

72.87%

24

United Kingdom

51.42%

53

Thailand

62.53%

82

Greece

73.41%

25

Chinese Taipei

52.65%

54

Philippines

62.55%

83

Kazakhstan

74.00%

26

Spain

52.94%

55

Latvia

62.62%

84

Azerbaijan

77.20%

27

Malta

54.64%

56

Peru

63.18%

85

Armenia

78.17%

28

Austria

55.26%

57

Estonia

64.09%

29

Slovakia

55.46%

58

Panama

64.40%

Table 4 lists all countries included in the study ranked by Mortality to Incidence
Ratio (M/I) as a percentage. Countries in red are high income as decided by the study
parameter of GDP>$15,000 while countries in green are low income (GDP<$15,000). In
general, high income countries have lower M/I when compared to their low income
counterparts.
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Table 5. Significantly Correlating Variables by Sex and Income Category

Sex

Male &
Female

Female

Male

Variable

1% change
in M/I

HIGH INCOME
95% Confidence
Interval

p-value

1% change
in M/I

LOW INCOME
95% Confidence
Interval

p-value

WHO Overall Score

-

-

-

7.0%

(3.8%, 44.4%)

0.022

WHO Responsiveness Score

2.0%

(1.1%, 7.5%)

0.009

-

-

-

GDP

$3,040

($1828, $9091)

0.004

-

-

-

THE

$379

($248, $800)

<0.0001

-

-

-

THE/GDP

0.75%

(0.46%, 1.95%)

<0.0001

-

-

-

TEBD per 100,000

0.59

0.027

-

-

-

TEBD/THE

-0.031%

(0.31, 4.93)
(-0.112%, 0.018%)

0.008

-

-

-

Physicians per 100,000

-

-

-

-39

(-74, -26)

<0.001

WHO Overall Score

-

-

-

-

-

-

WHO Responsiveness Score

2.8%

(1.6%, 20.1%)

0.024

-

-

-

GDP

$3,745

($2128, $15649)

0.012

-

-

-

THE

$575

($333, $2105)

0.008

-

-

-

THE/GDP

1.30%

(0.68%, 13.76%)

0.031

-

-

-

TEBD per 100,000

-

-

-

-

-

TEBD/THE

-0.037%

(-0.15%, 0.021%)

0.011

-

-

-

Physicians per 100,000

-

-

-

-56

(-260, -31)

0.01

WHO Overall Score

-

-

-

-

-

-

WHO Responsiveness Score

1.7%

(1.0%, 5.3%)

0.005

-

-

-

GDP

$2,667

($1642, $7092)

0.002

-

-

-

THE

$358

($229, $820)

0.001

-

-

-

THE/GDP

0.76%

(0.45%, 2.53%)

0.006

-

-

-

TEBD per 100,000

0.54

(0.28, 6.4)

0.033

-

-

-

-0.031%

(-0.118%, 0.018%)

0.009
-42

(-91, -27)

0.001

TEBD/THE
Physicians per 100,000

Table 5 shows significant correlates of overall cancer mortality to incidence ratio
(M/I), as well as the increase in each variable needed to cause a 1% decrease in
cancer mortality (1% change in M/I). For example, in high income countries, a $3,040
increase in GDP per capita is associated with a 1% decrease in overall cancer
mortality (p=0.004). While GDP, THE, THE per GDP, WHO responsiveness score and TEBD
all showed significant inverse correlations with mortality in high income countries,
THE and THE per GDP showed the strongest correlations (highest R and lowest p-value).
In low income countries, only WHO overall score correlated with decreased overall
cancer mortality while physician density paradoxically correlated with increased
mortality. (GDP = Gross Domestic Product per capita, WHO = World Health Organization,
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THE = total health expenditure per capita, TEBD = Total external beam radiation
devices per 100,000 population, Physician Density = Physicians per 100,000 population)

A 1% decrease in overall cancer M/I correlated to a 2.0% increase in
WHO responsiveness score (p=0.009). Specifically, improvement in WHO
responsiveness score was associated with significant decrease in M/I of
stomach, kidney, colon, breast, cervix, CNS, testis, non-Hogdkin
lymphoma, and head and neck cancers.
GDP, THE and THE per GDP:
In low income countries, GDP, THE and THE per GDP did not
correlate with overall cancer M/I in any sex category. Interestingly,
M/I correlated positively with GDP for Lung, pancreas, stomach, and
cervical cancer, meaning that as GDP increased in low income countries,
survival decreased for these cancers. Only Hodgkin lymphoma had the
expected inverse correlation with GDP.

No individual cancer showed any

significant correlation with THE, and only the M/I of gallbladder
cancer in men showed a significant inverse correlation with THE.
In high income countries, GDP, THE and THE per GDP all correlated
significantly with overall cancer M/I in all three sex categories. In
both sexes combined, a 1% decrease in overall cancer mortality
correlated with an increase of $3,040 for GDP (p=0.004), $379 for THE
(p<0.0001) and 0.75% of GDP for THE per GDP (p<0.0001). The following
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cancers had a significant inverse correlation with all three variables:
colorectal, breast, cervix, liver, CNS, kidney, stomach, testis, liver
and head and neck. Non-Hodgkin lymphoma, lung and bladder

cancer

correlated with both THE and GDP but not THE per GDP, while a few
cancers correlated only with each individual variable. For overall
cancers, M/I correlated most significantly with THE, as evidenced by
the fact that its p value was lowest in all three sex categories (See
Table 5). Two of the three countries with the absolute lowest overall
cancer M/I’s, Luxembourg (0.386) and the United States(0.394), also
had the highest THEs at $7439 and $7285 respectively.
TEBD and Physician Density
In low income countries, TEBD did not correlate significantly
with overall cancer M/I. Physician density, surprisingly, showed a
positive correlation in all three sex categories (p= 0.009), with an
increase of 39 physicians per 100,000 leading to a 1% increase in
overall cancer M/I for both sexes. Specifically, colorectal, Hodgkin
lymphoma, head and neck, and ovarian cancer M/Is correlated
significantly with physician density.
In high income countries, TEBD showed a significant inverse correlation
with the M/I of overall cancers in men alone and both sexes combined
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(0.027), but not in women alone. For overall cancer, a 1% decrease in
M/I correlated with an increase of 0.59 external beam devices per
100,000 population. M/I of colorectal, CNS, stomach, liver, breast,
lung, cervix, head and neck cancers correlated significantly with TEBD.
Physician density on the other hand, correlated poorly with M/I in
these countries.
Discussion:
Cancer mortality varied widely throughout the developed and
developing world. Quantifiable measures of overall monetary resources,
healthcare infrastructure, and healthcare system organization appeared
to impact cancer mortality in different ways in higher vs. lower income
countries. While financial resources and infrastructure showed
significant correlations with overall cancer mortality in high income
countries, low income countries showed correlations with none of these
factors. This was not simply due to lack of power, as some measures of
resources showed paradoxical weak (not statistically significant)
positive correlations with mortality. For low income countries, WHO
overall healthcare system score was the only variable strongly
associated with improvement in overall cancer mortality. This score
took into account not only general population health but also a
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system’s responsiveness to its patients and the equitable distribution
of health and healthcare within a country. This finding suggests that
for poor countries, increased healthcare expenditure may not
significantly improve national cancer mortality in the presence of
unequal distribution of healthcare resources.

Indeed there may be a

minimum threshold beyond which an increase in healthcare expenditure
and infrastructure is associated with improved cancer mortality.
While WHO overall healthcare score was associated with improved
cancer mortality in low income countries, no association was seen in
high income countries.

The differential results in high vs. low income

countries at the same time validate and undermine the utility of the
WHO score in assessing a healthcare system’s ability to treat cancer
effectively. The score’s relationship with the end-measure of
mortality depends on context. As noted previously, a large part of the
WHO healthcare system score is based on the equality of health
resources distribution. In the setting of relatively low national
resources, equality is very important – to spread out the limited
healthcare expenditure available so that everyone has access to the
most basic cancer screening and treatment.

In high income countries,

because the most modern cancer treatment is so expensive (11), it may
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be difficult to provide the most technologically advanced treatments to
every single person that needs it.

More equitable high income

nationalized systems may choose not to offer the most advanced
treatments at all in order to limit costs and focus more on less
expensive diseases. Thus, high income countries which offer the most
advanced but expensive treatments to only a portion of the population,
may have an edge in overall cure rates compared to their more equitable
counterparts.
Among the variables chosen, the WHO score had particular
drawbacks but also particular promise. A small portion of the score was
based on national levels of health measured by disability adjusted life
years lost to disease. As our dependent variable was cancer mortality,
and higher cancer mortality within a country would potentially lead to
poorer national levels of health, it was hypothesized that there could
be the potential of testing a circular relationship. However, as this
relationship was only a small part of the overall relationship being
tested, it was decided to include the WHO score as a variable. The
complexity of the score’s algorithm, a source of much debate in the
scientific community, was another reason the score was chosen. The
score attempted the herculean task of quantifiably measuring the
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overall fairness and effectiveness of a healthcare system. Thus, in our
model it served as a gestalt measure of a healthcare system’s
performance and organization to counterbalance the very specific
measures of resources and infrastructure. While the merits and pitfalls
of this score could be debated endlessly, the significant correlation
between the score and overall cancer mortality in low income countries
provides partial evidence in support of the score’s utility. At the
very least, this result should fuel further research on the
relationship between the score and health outcomes.
The first question that arises from the above results is why do
WHO overall healthcare system scores fail to predict cancer outcomes in
high income countries? Cancer treatment is a resource intensive
process. In the United States for example, the average cost of initial
treatment for colorectal and lung cancer, two of the most common
cancers worldwide, are between $60,000 and $75,000 per person (11).
Expensive chemotherapeutic agents, surgeries and radiation treatments
are required, often for only a small chance of improvement or cure.
However, without these expensive and aggressive treatments, the chances
of improvement or cure would be even less. A large part of the WHO
overall healthcare system score is based on the equity of health
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resources distribution. In more equitable healthcare systems, which
would gain a higher rank, there is more of a managed care approach; as
such, expensive treatments with small chances of causing an improvement
in survival are often not undertaken for financial reasons (12, 13).
Thus, in high income countries, an improvement in WHO overall
healthcare system rank would not necessarily lead to improved cancer
survival, as a managed care or nationalized healthcare approach with
more equitable distribution of resources would potentially limit the
aggressiveness of treatment of patients with poorer prognoses and
diseases that have very expensive treatments. On the contrary, in a
less equitable system that has components which are fee for service,
there is greater physician incentive for more costly and aggressive
treatments, and less pressure to control costs (14). This more
aggressive care could potentially result in improved cancer survival on
the whole, albeit at high costs. Thus it is also not surprising that
THE correlates so significantly with survival in high income countries.
In low income countries on the other hand, greater equity in
access to healthcare and cost distribution means that at least the
majority of the population have access to the most inexpensive cancer
treatments. This explains why WHO overall healthcare rank correlates
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well with survival in low income countries. However, another question
that arises is why do healthcare system resources such as THE or TEBD
fail to predict outcomes in low income countries? One possible answer
is that the variation in these indicators is too small in low income
countries to show any predictive value. For example, the range of THE
in low income countries is $634 ($29 in Tajikistan to $663 in
Argentina), while it is $6,732 ($716 in Poland to $7439 in Luxembourg)
in high income countries. Similar disparities in range exist for GDP,
TEBD and THE per GPD.

This finding suggests one of two things: that

the variation in resources was too small in low income countries to
show a statistically significant correlation with survival given the
relatively small sample size, or, that there may be a threshold before
which resources cannot cause an improvement in cancer survival. Further
research is necessary to determine whether this threshold exists and
what values of GDP, THE, THE per GDP or TEBD prove to be cutoff points
before which significant improvement in cancer outcomes are not seen.
While GDP, overall healthcare expenditure, expenditure as a
proportion of GDP, and access to radiation oncology were all
significant inverse correlates of mortality in high income countries,
the overall data suggests that overall healthcare expenditure showed
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the strongest correlation. Thus, in countries with a GDP>$15,000,
healthcare spending truly does make a difference in fighting cancer,
both as an absolute value, and as a proportion of a nation’s budget.
The most significant difference is seen in the most treatment and
screening sensitive cancers, namely breast and colorectal cancer.
Access to radiation therapy (as measured by total external beam devices
per capita) also has the strongest association with both of these
cancers, where adjuvant radiation therapy is often the standard of
care.
Limiting our study was the lack of data on the poorest of all
countries, particularly those in Africa. African countries have a per
capita GDP on average less than half of the next most resource limited
continent, Asia.

However, the burden of cancer is huge in Africa. For

example, the risk of dying from cancer among African women is actually
double that of developed countries (15). Thus, future research
attempting to analyze correlates of cancer mortality in the poorest of
poor countries is an absolute necessity. Another limitation was the
potential impact of unmeasured variables on cancer outcomes. For
example, expenditure on social welfare has been shown to be an
independent correlate of general health outcomes in developed
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countries, even surpassing healthcare expenditure itself in some
countries (7).
One very surprising result was that physician density not only
failed to correlate with survival in high income countries, but it also
had a significant inverse correlation with survival (direct correlation
with M/I) in low income countries. This result ties in perfectly with
geography and politics. Of the 18 low income countries with the highest
physician density, 17 are current or former communist countries,
including Cuba, former members of the Soviet Union and the Eastern
Bloc. On the other hand, the vast majority of low income countries with
the lowest physician densities are Latin American countries with no
strong history of communism. This trend can easily be seen by looking
at the color difference between Soviet and Eastern Bloc countries vs.
Central and South American ones in Figure 1. It is understandable that
countries with communist backgrounds employ more socialized healthcare
systems with more centralized systems of physician training and higher
physician densities (16). However, why do these countries also have
poorer survival rates? This difference cannot fully be explained by
economic factors as several of the countries in Latin America for
example have equal or lower GDPs and THEs to those in Eastern Europe,
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but better survival rates. One possible explanation ties this result
back to the previous comparison of managed care vs. fee for service
based healthcare systems. Current or former communist countries are
more likely to have a population-based approach to healthcare rather
than an individual based approach, thus putting less emphasis on
treating individuals with costly diseases than in treating cheaper
diseases that are deemed treatment worthy by the state (17).
While GDP, THE, THE per GDP, TEBD and WHO responsiveness score
were all significant positive correlates of survival in high income
countries, the overall data suggests that THE is the strongest
predictor. Due to the collinearity of the aforementioned variables,
parsing out the importance of one over the other posed a significant
challenge. The first and simplest way of comparing effects was to
compare the p-value of each correlation. THE and THE per GDP had the
lowest p-values at p<0.0001 in the both sexes category, while THE alone
won the battle in each sex individually. Since THE per GDP is
combination of THE and the inverse of GDP, it is a useful variable in
assessing the relative strength of the two. Thus, the fact that THE per
GDP showed a significant inverse correlation with M/I supports the
hypothesis that THE has greater predictive value than GDP. It is also
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quite possible, that because all of the above variables are collinear,
either a common underlying variable or THE alone is accountable for the
correlations seen.
Considering the cost of modern cancer care, the apparent effect
of THE on survival is not at all surprising. Any potential effect of
THE on M/I will have to come through one of two routes: improved cancer
screening leading to detection at earlier stages, or, improved
treatment after detection. If the former were the case, the most common
cancers for which there are widely established screening mechanisms
(such as colon, breast and prostate cancer) and effective early stage
treatment would be most affected by rising THE. If the latter were the
case, THE’s effects would be most pronounced in the most costly
cancers to treat. Using recently published data from Mariotto et al.
2011 regarding the cost of treatment by cancer in the United States, as
well as our global incidence and mortality data, we wished to see
whether THE was more likely to correlate with the M/I for higher
costing and more prevalent cancers (11). However, no relationship was
found in either case. While it was true that the M/I of costly cancers
(such as CNS cancers) and common treatable cancers (such as colorectal
and breast cancer) correlated significantly with THE, so did several
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cancers that were relatively uncommon and inexpensive to treat. Thus
the mechanism of any potential effect of THE on M/I remains uncertain.
In high income countries, every single significantly correlating
variable (THE, GDP, THE/GDP, WHO responsiveness score, TEBD) showed a
much stronger correlation with M/I in men than women (as evidenced by a
lower p-value). This result held both for overall cancers and head to
head comparisons of individual cancers. Such a finding would lead us to
believe that improvements in healthcare system resources have a
potentially stronger effect on men than women. But why would this be?
Traditionally, women are seen as the sex that takes better care of
their health and visits the doctor more frequently. Several studies
have found that women have higher overall utilization of the healthcare
system in the United States (18). So what exactly is it about cancer
care that’s different in men than women? A British study found that in
a cohort of 5462 community members, men were significantly more likely
to take part in colon cancer screenings than women (19). A Japanese
study found that women with stomach cancer (the most common cancer in
the country) presented at a significantly later stage than men, and
consequently had decreased survival rates (20). Thus perhaps when it
comes to certain common cancers, women are for some reason less likely
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to undergo screening, and more likely to present at later stages. This
hypothesis would explain why improvement in healthcare systems and
healthcare resources would have less of an effect on women than men.
In this paper, we have shown the importance of financial
resources in predicting survival in high income countries compared to
the primacy of healthcare system organization as determined by the WHO
in low income countries.

While we have shown differences in the

strength of effect of each variable, it is difficult to be certain of
how direct the effect is. As this is a retrospective correlational
study, the potential covert effect of one or several unknown variables
that dictates the above healthcare system indicators cannot be
excluded. Additionally, despite efforts to separate the effects of each
variable, a more complex interdependent relationship between all of the
healthcare system indicators in predicting M/I is likely. This point is
clearly evidenced in the above discussion regarding physician density
in former Communist countries. It is also important to note the
geographic limitations of this study. As the study was limited to
countries with robust data collection mechanisms, the vast majority of
Africa and a significant portion of Asia were excluded. Thus, the
results cannot be extrapolated to these areas. That being said, the
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range of countries sampled was quite broad, with many countries having
a THE that was greater than the entire GDP of their counterpart. The
United States’ THE of 7285 for example was four times the GDP of
Turkmenistan.
This report opens up more questions than it answers, especially
in regards to finding the optimal healthcare system for treating
cancer. On some levels, our study provides justification for the
seemingly astronomical costs of medical care in many developed
countries such as the United States. The higher costs actually produce
real improvements in cancer survival. Additionally, despite many
concerns related to healthcare access and equitability in more complex
fee for service systems such as that of the United States, such
countries often outperform more equitable systems in cancer survival.
However, as this was a correlational study, further analyses are
required. Specifically, studies are necessary to find additional hidden
factors that may predict cancer survival and parse out the extent and
mechanism of influence of both known and unknown factors.
Conclusion
This paper serves as the first analysis to explore the
relationship between healthcare system indicators and cancer outcomes
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across the globe. Cancer mortality varied widely throughout high and
low income countries. While overall financial resources and healthcare
infrastructure were strongly associated with cancer mortality in high
income countries, the World health Organization’s healthcare system
score, a measure of healthcare system performance, organization and
equality, was the only correlate of mortality in low income countries.
This suggests a greater importance of healthcare system structure and
equality in lower income countries vs. absolute levels of resources in
higher income countries.
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